Clonidine 25 mcg tablets
Indication
Vasomotor symptoms (VMS) associated with menopause
Green (Restricted)
Brand:
Nice TA:
Commissioning responsibility:
CCG
PbR excluded:
No
BNF chapter:
Endocrine system
Background
Hormone replacement therapy (HRT) is the first-line treatment for menopausal VMS.
Where HRT is contraindicated or declined, a trial of Clonidine 25 mcg tablets may be considered for menopausal VMS.
Patients should be reviewed after 4 weeks and if no improvement in symptoms is observed or the patient is experiencing significant adverse events, treatment should be discontinued.
Recommendation
LSCMMG Recommendation:
Green (Restricted)
Reason for decision:
Suitable for initiation in primary care in line with restrictions
Supporting documents: